![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ZNF420 |
Gene summary for ZNF420 |
![]() |
Gene information | Species | Human | Gene symbol | ZNF420 | Gene ID | 147923 |
Gene name | zinc finger protein 420 | |
Gene Alias | APAK | |
Cytomap | 19q13.12 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q8TAQ5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
147923 | ZNF420 | male-WTA | Human | Thyroid | PTC | 2.29e-02 | 4.62e-02 | 0.1037 |
147923 | ZNF420 | PTC04 | Human | Thyroid | PTC | 1.93e-02 | 3.35e-02 | 0.1927 |
147923 | ZNF420 | PTC05 | Human | Thyroid | PTC | 2.65e-03 | 1.55e-01 | 0.2065 |
147923 | ZNF420 | PTC06 | Human | Thyroid | PTC | 4.46e-05 | 9.09e-02 | 0.2057 |
147923 | ZNF420 | PTC07 | Human | Thyroid | PTC | 2.58e-09 | 8.30e-02 | 0.2044 |
147923 | ZNF420 | ATC13 | Human | Thyroid | ATC | 1.28e-76 | 1.33e+00 | 0.34 |
147923 | ZNF420 | ATC2 | Human | Thyroid | ATC | 7.45e-04 | 2.54e-01 | 0.34 |
147923 | ZNF420 | ATC5 | Human | Thyroid | ATC | 9.49e-85 | 1.42e+00 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF420 | SNV | Missense_Mutation | c.1853N>A | p.Arg618Lys | p.R618K | Q8TAQ5 | protein_coding | tolerated(1) | benign(0) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
ZNF420 | SNV | Missense_Mutation | rs765172465 | c.1708N>T | p.Arg570Cys | p.R570C | Q8TAQ5 | protein_coding | tolerated(0.24) | possibly_damaging(0.865) | TCGA-AC-A8OP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZNF420 | SNV | Missense_Mutation | c.1287N>A | p.Asn429Lys | p.N429K | Q8TAQ5 | protein_coding | tolerated(0.22) | possibly_damaging(0.572) | TCGA-AR-A1AI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | PD | |
ZNF420 | SNV | Missense_Mutation | novel | c.1307N>T | p.Arg436Leu | p.R436L | Q8TAQ5 | protein_coding | tolerated(0.61) | benign(0.286) | TCGA-AR-A2LE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | PD |
ZNF420 | SNV | Missense_Mutation | c.1193A>G | p.Lys398Arg | p.K398R | Q8TAQ5 | protein_coding | deleterious(0.01) | benign(0.003) | TCGA-BH-A0HU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | |
ZNF420 | insertion | Frame_Shift_Ins | novel | c.63_64insATAAAATGCTTGTGTATGCTACTTCTTTTAAT | p.Cys22IlefsTer24 | p.C22Ifs*24 | Q8TAQ5 | protein_coding | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
ZNF420 | insertion | Frame_Shift_Ins | novel | c.752_753insCAATT | p.Glu252AsnfsTer101 | p.E252Nfs*101 | Q8TAQ5 | protein_coding | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
ZNF420 | insertion | Nonsense_Mutation | novel | c.754_755insTTTCTGTTATTGTTGAGTAATGTTGCATGAATC | p.Glu252delinsValSerValIleValGluTerCysCysMetAsnGln | p.E252delinsVSVIVE*CCMNQ | Q8TAQ5 | protein_coding | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
ZNF420 | SNV | Missense_Mutation | c.961N>G | p.Gln321Glu | p.Q321E | Q8TAQ5 | protein_coding | tolerated(0.75) | benign(0.371) | TCGA-DS-A1OD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
ZNF420 | SNV | Missense_Mutation | c.1836N>C | p.Glu612Asp | p.E612D | Q8TAQ5 | protein_coding | deleterious(0.01) | probably_damaging(0.962) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |